MAK683 / Novartis 
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MAK683 / Novartis
NCT02900651 / 2016-001860-12: Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Active, not recruiting
1
139
Europe, Canada, Japan, US, RoW
MAK683
Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma
09/24
09/24

Download Options